The acquisition is part of McKesson's strategy to expand its footprint in the retina and ophthalmology care sectors, building on its existing community practice and specialty solutions.

McKesson delivered strong Q3 2025 results ... The acquisition of PRISM Vision marks a significant step into ophthalmology, building on its proven oncology platform. While management raised ...

McKesson expects PRISM Vision to add about 20 cents to 30 cents to its adjusted earnings per share in the first 12 months following the close of the transaction, and then to be between 65 cents and 75 ...

Healthcare distribution and services specialist McKesson (NYSE:MCK) reported mixed financial results for fiscal 2025's third quarter on Wednesday, Feb. 5. McKesson beat earnings expectations with ...

“The acquisition of PRISM Vision will allow McKesson to build on our leadership in community practice and specialty solutions, while building a platform to serve the high-growth area of retina ...

McKesson is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $280 billion in sales from its US pharmaceutical segment in fiscal ...